Alk-Abello, INC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.3Mgeneral payments (2019-2025)
$20Kresearch payments (2019-2025)
13,021clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Odactra $652K associated (2023-2025)
- Grastek $501K associated (2023-2025)
- Ragwitek $459K associated (2023-2025)
- Neffy $229K associated (2023-2025)
- Standardized Mite D. Farinae $15K associated (2023-2025)
- Timothy, Standardized $15K associated (2023-2025)
- Alternaria Tenuis $15K associated (2023-2025)
- Pre-Pen $10K associated (2023-2025)
- Histamine Positive $4,208 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Jacqueline Eghrari-Sabet | Vienna, VA | Allergy & Immunology | $252,499.05 |
| Lara Gross | Dallas, TX | Allergy & Immunology | $52,909.87 |
| Michael Tankersley | Collierville, TN | Allergy & Immunology | $47,820.72 |
| Lawrence Dubuske | Washington, DC | Allergy & Immunology (Internal Medicine) | $46,038.90 |
| Vinay Mehta | Laguna Niguel, CA | Allergy & Immunology | $46,031.42 |
| Sally Bailey | Baltimore, MD | Allergy & Immunology (Internal Medicine) | $45,530.01 |
| Michael Blaiss | Roswell, GA | Allergy & Immunology | $42,517.93 |
| Priya Bansal | Saint Charles, IL | Allergy & Immunology | $37,297.60 |
| Bruce Prenner | San Diego, CA | Allergy & Immunology | $36,586.57 |
| Michelle Yasharpour | Beverly Hills, CA | Allergy | $35,666.98 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.